These agonists can activate the cGAS-STING pathway in immune cells, promoting an anti-tumor response.360,361 Combining STING agonists with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 therapies, may enhance the immune system’s ability to recognize and destroy tumors. Here, PDCD1 is linked to neoplasm.